- Home
- INO vs PCF Comparison
INO vs PCF Comparison
Compare INO & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- PCF
- Stock Information
- Founded
- INO 1979
- PCF 1987
- Country
- INO United States
- PCF United States
- Employees
- INO N/A
- PCF N/A
- Industry
- INO Medical/Dental Instruments
- PCF Trusts Except Educational Religious and Charitable
- Sector
- INO Health Care
- PCF Finance
- Exchange
- INO Nasdaq
- PCF Nasdaq
- Market Cap
- INO 136.6M
- PCF 116.8M
- IPO Year
- INO 1998
- PCF N/A
- Fundamental
- Price
- INO $2.58
- PCF $6.27
- Analyst Decision
- INO Buy
- PCF
- Analyst Count
- INO 5
- PCF 0
- Target Price
- INO $8.80
- PCF N/A
- AVG Volume (30 Days)
- INO 1.0M
- PCF 74.8K
- Earning Date
- INO 11-10-2025
- PCF 01-01-0001
- Dividend Yield
- INO N/A
- PCF 10.90%
- EPS Growth
- INO N/A
- PCF N/A
- EPS
- INO N/A
- PCF N/A
- Revenue
- INO $182,337.00
- PCF N/A
- Revenue This Year
- INO N/A
- PCF N/A
- Revenue Next Year
- INO $14,751.49
- PCF N/A
- P/E Ratio
- INO N/A
- PCF N/A
- Revenue Growth
- INO N/A
- PCF N/A
- 52 Week Low
- INO $1.30
- PCF $5.71
- 52 Week High
- INO $5.80
- PCF $6.96
- Technical
- Relative Strength Index (RSI)
- INO 58.30
- PCF 45.83
- Support Level
- INO $2.21
- PCF $6.17
- Resistance Level
- INO $2.49
- PCF $6.30
- Average True Range (ATR)
- INO 0.14
- PCF 0.05
- MACD
- INO -0.01
- PCF 0.00
- Stochastic Oscillator
- INO 81.29
- PCF 61.17
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.